Maisha Meds, a Kenyan-based digital pharmacy community which supplies a enterprise administration software program and reimbursement packages for pharmacies, drug outlets and clinics, and affected person assist through its point-of-sale pharmacy app, has obtained US$5.25 million in scale-up stage 3 funding from the US Company for Worldwide Growth (USAID) Growth Innovation Ventures (DIV).
The funding which shall be disbursed in three years, is aimed to assist Maisha Meds’ enlargement efforts to succeed in folks in want of reasonably priced, high-quality malaria care throughout Africa by non-public drug outlets, pharmacies, and clinics that always function their first and typically solely level of care.
“Frontline pharmacies present the majority of malaria care throughout many elements of Africa outdoors of the formal well being system, and expertise can play an essential function in enhancing the standard of care that they supply,” stated Dr Jessica Vernon, founder and chief government officer of Maisha Meds.
“We’re thrilled that USAID DIV has offered further assist to scale our innovation in partnership with governments and pharmacy house owners.”
Based in 2017 ,Maisha Meds is a software program platform with operations throughout Kenya, Uganda, Tanzania, Nigeria and Zambia, Maisha Meds has over the previous few years grown to assist over 4 million affected person encounters yearly throughout its markets with its suite of software program merchandise.
With further assist from the Invoice & Melinda Gates Basis, Maisha Meds goals to increase its cellular software program to 7,500 pharmacies and clinics by the tip of the grant interval, delivering backed care to just about 1,000,000 sufferers.
Stage 3 grants which is DIV’s highest degree of funding, assist innovators scale up confirmed, cost-effective approaches to vital international challenges.
Maisha Meds companions embrace USAID Growth Innovation Ventures, the Invoice & Melinda Gates Basis, the Youngsters’s Funding Fund Basis, Grand Challenges Canada, Pfizer, and others.